Evidence map›Paper›PMID 32340255›Full record

ArticleMolecules (Basel, Switzerland)2020

5-(1

Volodymyr Horishny, Victor Kartsev, Athina Geronikaki, Vasyl Matiychuk, Anthi Petrou, Jasmina Glamoclija, Ana Ciric, Marina Sokovic

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Volodymyr HorishnyDepartment of Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine.
Victor KartsevInterBioScreen, 85355 Moscow, Russia.
Athina GeronikakiDepartment of Phram Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0001-9894-7777
Vasyl MatiychukDepartment of Chemistry, Ivan Franko National University of Lviv, Kyryla i Mefodia 6, 79005 Lviv, Ukraine.
Anthi PetrouDepartment of Phram Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0001-8587-2710
Jasmina GlamoclijaMycological Laboratory, Institute of Biological Research Sinisa Stankovic, National Institute of Republic of Serbia, Belgrade University, 11000 Belgrade, Serbia.
Ana CiricMycological Laboratory, Institute of Biological Research Sinisa Stankovic, National Institute of Republic of Serbia, Belgrade University, 11000 Belgrade, Serbia.ORCID 0000-0002-9478-5448
Marina SokovicMycological Laboratory, Institute of Biological Research Sinisa Stankovic, National Institute of Republic of Serbia, Belgrade University, 11000 Belgrade, Serbia.ORCID 0000-0002-7381-756X
University of Belgrade · RSAristotle University of Thessaloniki · GRDanylo Halytsky Lviv National Medical University · UALviv University · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfectious diseases symbolize a global consequential strain on public health security and impact on the socio-economic stability all over the world. The increasing resistance to the current antimicrobial treatment has resulted in crucial need for the discovery and development of novel entity for the infectious treatment with different modes of action that could target both sensitive and resistant strains.

methodsCompounds were synthesized using classical methods of organic synthesis.

resultsAll 20 synthesized compounds showed antibacterial activity against eight Gram-positive and Gram-negative bacterial species. It should be mentioned that all compounds exhibited better antibacterial potency than ampicillin against all bacteria tested. Furthermore, 18 compounds appeared to be more potent than streptomycin against

conclusionAll tested compounds showed good antibacterial and antifungal activity better than that of reference drugs and three the most active compounds could consider as lead compounds for the development of new more potent agents.

Indexed as

Anti-Infective AgentsChemistry Techniques, SyntheticHeterocyclic CompoundsMolecular ConformationMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureStructure-Activity RelationshipAnti-Infective AgentsHeterocyclic CompoundsantifungalantimicrobialCandida albicans 14α-demethylaseCYP51E. coli MurBindolemolecular docking

Identifiers

PMID32340255
PMCPMC7221690
OpenAlexW3017976874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.